Investment Objective
The fundamental investment
objective of the Fund is to
achieve long-term capital
appreciation by investing
primarily in equity securities
of companies located in the
United States and other
countries that are engaged in
the research, development,
production, or distribution of
products or services related
to health care, medicine, or
the life sciences. Health
sciences companies are defined
as those companies that commit
or derive at least 50% of
their assets, revenues, or
operating profits from the
activities just described.
Benchmark Statement
Lipper Health/Biotechnology
Funds Index (C$)
Recommended For
This Fund may be suitable for
long-term investors who are
contributing to the growth
component of a diversified
portfolio, want exposure to
the rapidly advancing health
sciences sector and willing to
accept some short-term
volatility for potentially
higher long-term returns.
Investors in this Fund should
be willing to accept a high
level of risk.
Why Invest
You can benefit from the
expected growth in
health care spending, research
and development.
The Fund aims to deliver
superior returns
relative to the investment
risk involved.
Portfolio Update
Quarterly Update
Stock selection was the primary driver of performance relative to the Lipper Health/Biotechnology Funds (C$) benchmark, while sector allocation was relatively inconsequential. On the upside, holdings in the life sciences, products and devices, and services sectors drove performance. Stock selection detracted from relative performance in the biotechnology and pharmaceuticals sectors, offsetting strong relative performance elsewhere. The Fund’s sector weights were relatively similar to those in the benchmark, though a slight overweight in the services sector and a small underweight in the biotechnology sector were beneficial.
(December 2012)
General Description
| Fund Codes:
|
TDB976
|
| Minimum non-RSP Investment:
|
$ 100.00
|
| Minimum RSP Investment:
|
$ 100.00
|
| Minimum Subsequent Investment:
|
$ 100.00
|
| Early Redemption:
|
Up to 2.00% of purchase cost
if redeemed within 30 days of
purchase.
|
|
MER:
|
2.82% MER as of December 31, 2012
|
| Sector Class:
|
Health Care Equity
|
| Inception Date:
|
Oct. 30, 1996
|
| Assets:
|
$ 286.04 million as of Apr. 30, 2013.
|
| Minimum PPP Amount:
|
$25.00
|
|
News
Sorry there are no news articles available.
Downloads
Internet Security
